Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma (mRCC): A new surgical challenge?
Abstract only 707 Background: In the current era of Immune checkpoint inhibitors (ICI), the role and timing of nephrectomy in the case of complete response on metastatic sites is still unknown. We aimed to evaluate the feasibility of nephrectomy for residual disease in patients with metastatic renal...
Saved in:
Published in: | Journal of clinical oncology Vol. 38; no. 6_suppl; p. 707 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
20-02-2020
|
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Abstract only 707 Background: In the current era of Immune checkpoint inhibitors (ICI), the role and timing of nephrectomy in the case of complete response on metastatic sites is still unknown. We aimed to evaluate the feasibility of nephrectomy for residual disease in patients with metastatic renal cell carcinoma (mRCC) and complete response (CR) on metastatic sites following ICI. Methods: Patients who underwent partial or radical nephrectomy after prior ICI between 2015 and 2018 were retrospectively included and clinicopathological data were reviewed. Perioperative data and postoperative outcomes were recorded. Results: Eleven patients without initial cytoreductive nephrectomy at diagnosis underwent delayed nephrectomy after long ICI administration because of complete response on metastatic sites. Median age was 59.8 years [38-67]. All patients had clear cell RCC on the initial biopsy. IMDC prognostic group was intermediate (81.8%) or poor (18.2%). ICI was administered as first-line therapy in 36.4% of cases (4/11) and as second-line option after TKI in 63.6% of cases (7/11). Treatments regimens were: nivolumab + ipilimumab (n = 3), nivolumab + tivozanib (n = 2) or nivolumab alone (n = 6). The median duration of ICI treatment was 10 months (range: 3-38 months) and the mean number of cycles was 27 (range: 6-75). Median operative time was 243 minutes [135-345] and mean blood loss was 909 cc [40-4000]. In 81.8% (n = 9) of the cases, surgeons experienced challenges for finding dissection planes due to inflammatory infiltration. The 30-day Clavien-Dindo postoperative complication rate was 54.6%, including 1 surgery-related death. Pathological report showed lymphocyte and/or macrophage infiltration in 54.6% and complete pathological response in 2 cases. Median follow-up was 15 months, with 73% of patients free from progression and 54% free from systemic treatment at 1 year. Conclusions: Nephrectomy following ICI for mRCC could allow achieving CR in selected patients. Due to technically complexity and complications rates, this surgery should be performed in centers with extensive experience. |
---|---|
AbstractList | Abstract only 707 Background: In the current era of Immune checkpoint inhibitors (ICI), the role and timing of nephrectomy in the case of complete response on metastatic sites is still unknown. We aimed to evaluate the feasibility of nephrectomy for residual disease in patients with metastatic renal cell carcinoma (mRCC) and complete response (CR) on metastatic sites following ICI. Methods: Patients who underwent partial or radical nephrectomy after prior ICI between 2015 and 2018 were retrospectively included and clinicopathological data were reviewed. Perioperative data and postoperative outcomes were recorded. Results: Eleven patients without initial cytoreductive nephrectomy at diagnosis underwent delayed nephrectomy after long ICI administration because of complete response on metastatic sites. Median age was 59.8 years [38-67]. All patients had clear cell RCC on the initial biopsy. IMDC prognostic group was intermediate (81.8%) or poor (18.2%). ICI was administered as first-line therapy in 36.4% of cases (4/11) and as second-line option after TKI in 63.6% of cases (7/11). Treatments regimens were: nivolumab + ipilimumab (n = 3), nivolumab + tivozanib (n = 2) or nivolumab alone (n = 6). The median duration of ICI treatment was 10 months (range: 3-38 months) and the mean number of cycles was 27 (range: 6-75). Median operative time was 243 minutes [135-345] and mean blood loss was 909 cc [40-4000]. In 81.8% (n = 9) of the cases, surgeons experienced challenges for finding dissection planes due to inflammatory infiltration. The 30-day Clavien-Dindo postoperative complication rate was 54.6%, including 1 surgery-related death. Pathological report showed lymphocyte and/or macrophage infiltration in 54.6% and complete pathological response in 2 cases. Median follow-up was 15 months, with 73% of patients free from progression and 54% free from systemic treatment at 1 year. Conclusions: Nephrectomy following ICI for mRCC could allow achieving CR in selected patients. Due to technically complexity and complications rates, this surgery should be performed in centers with extensive experience. |
Author | Geoffrois, Lionnel Bensalah, Karim Barthelemy, Philippe Di Nunno, Vincenzo Gravis, Gwenaelle Ladoire, Sylvain Balssa, Loic Pignot, Geraldine Werle, Pierre Lang, Herve Walz, Jochen Leblanc, Louis Thiery-Vuillemin, Antoine Albiges, Laurence |
Author_xml | – sequence: 1 givenname: Geraldine surname: Pignot fullname: Pignot, Geraldine organization: Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France – sequence: 2 givenname: Antoine surname: Thiery-Vuillemin fullname: Thiery-Vuillemin, Antoine organization: University Hospital Jean Minjoz, Besançon, France – sequence: 3 givenname: Jochen surname: Walz fullname: Walz, Jochen organization: Institut Paoli-Calmettes, Chirurgie Oncologique 2, Marseille, France – sequence: 4 givenname: Herve surname: Lang fullname: Lang, Herve organization: Department of Urology, CHU Strasbourg, Strasbourg University, Strasbourg, France – sequence: 5 givenname: Pierre surname: Werle fullname: Werle, Pierre organization: Urology Department, University Hospital of Strasbourg, Strasbourg, France – sequence: 6 givenname: Loic surname: Balssa fullname: Balssa, Loic organization: Urology Department, Chru Besancon, Besancon, France – sequence: 7 givenname: Lionnel surname: Geoffrois fullname: Geoffrois, Lionnel organization: Centre Alexis Vautrin, Vandoeuvre-Lès-Nancy, France – sequence: 8 givenname: Louis surname: Leblanc fullname: Leblanc, Louis organization: Department of Urology, CHRU Nancy, Nancy, France – sequence: 9 givenname: Laurence surname: Albiges fullname: Albiges, Laurence organization: Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France – sequence: 10 givenname: Vincenzo surname: Di Nunno fullname: Di Nunno, Vincenzo organization: Department of medical oncology, Institut Gustave Roussy, Villejuif, France – sequence: 11 givenname: Karim surname: Bensalah fullname: Bensalah, Karim organization: University Hospital Pontchaillou Service d’urologie CHU Rennes, Université de Rennes, Rennes, France – sequence: 12 givenname: Sylvain surname: Ladoire fullname: Ladoire, Sylvain organization: Department of Medical Oncology, Center GF Leclerc, Dijon, France – sequence: 13 givenname: Gwenaelle surname: Gravis fullname: Gravis, Gwenaelle organization: Institut Paoli-Calmettes, Marseille, France – sequence: 14 givenname: Philippe surname: Barthelemy fullname: Barthelemy, Philippe organization: Hôpitaux Universitaires de Strasbourg, Strasbourg, France |
BookMark | eNot0M9KxDAQBvAgCq6rz2COetiaNE2TehEp_kUURMFbSLOT3WiblCSL7CP41nbRy3yXmYHvd4T2ffCA0CklBS0JuXhsX4qSlKRgsqhV2oxjXwgi9tCM8lIshOB8H82IYOWCSvZxiI5S-iSEVpLxGfp5hnEdweQwbLG2GSI2YRh7yIAjpDH4BDgH7IZh4wGbNZivMTifsfNr17kcYsI2RDxA1inr7Mx053WPDfTT0NE4HwaNz4bXtj2_xNfYwzdOm7hyZre11n0PfgVXx-jA6j7ByX_O0fvtzVt7v3h6uXtor58WhpKpj7bVkoA0NbWV7JjhnahlbaRljVh2XAOvlg0tte4aWnEQnbR103TSdLrmNbNsjsTfXxNDShGsGqMbdNwqStROVE2iaieqmFT_omoSZb91KXGf |
CitedBy_id | crossref_primary_10_1200_OP_21_00446 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1200/JCO.2020.38.6_suppl.707 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1527-7755 |
EndPage | 707 |
ExternalDocumentID | 10_1200_JCO_2020_38_6_suppl_707 |
GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AAQQT AARDX AAWTL AAYEP AAYXX ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL C45 CITATION CS3 DIK EBS EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 K-O KQ8 L7B LSO MJL N9A O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN SV3 TEORI TR2 TWZ UDS VVN WH7 X7M YCJ YFH YQY |
ID | FETCH-LOGICAL-c1027-af4d0e8c61f48b3c5b7686c8f397db5ae54d912aab9145e7b8f699b8cba6563f3 |
ISSN | 0732-183X |
IngestDate | Thu Nov 21 21:15:10 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6_suppl |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1027-af4d0e8c61f48b3c5b7686c8f397db5ae54d912aab9145e7b8f699b8cba6563f3 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1200_JCO_2020_38_6_suppl_707 |
PublicationCentury | 2000 |
PublicationDate | 2020-02-20 |
PublicationDateYYYYMMDD | 2020-02-20 |
PublicationDate_xml | – month: 02 year: 2020 text: 2020-02-20 day: 20 |
PublicationDecade | 2020 |
PublicationTitle | Journal of clinical oncology |
PublicationYear | 2020 |
SSID | ssj0014835 |
Score | 2.368287 |
Snippet | Abstract only 707 Background: In the current era of Immune checkpoint inhibitors (ICI), the role and timing of nephrectomy in the case of complete response on... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 707 |
Title | Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma (mRCC): A new surgical challenge? |
Volume | 38 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELbKIiEuCBYQb_kAK1A33TR2EocLWpWiRYjdCgrsLbIdByJosurjUP4B_5qZOA-zCMEeuEStVVtJ5ut4ZjwzHyGP4yzUcZwlnuSJ8riMlJcwX3hKBsKXJhI2efzofXx8Kl5O-XQwaHlH-7H_KmkYA1lj5ewFpN0tCgPwGWQOV5A6XP9J7scGxaPX1WLbEIDXWeNgGw-XNh-2JssosC7EDEFk-utZVZTIFPClUEVNvoOphwuzllhtVLd4RpMVQ_zYyFoXZbWQaJku3k0mT4LEFreDeT5cbZZWkeqWouVc3qBj_nYlmVWpfwntz4rPZbW28XqMlzkH_3Mk7t56HzdYwLjouh9Uzk8-yW_f7akAPFqfbtRExY8wv9MNdIBXi4XjvqMPYxZ4oIFO7dbV6OsgBgfBdvptFToTDnCjdIX0qI6Oji3NbrPdN99-20kCS5I9ORnhvYyYGDUrjbr5bu_uc3tql-mIPlaAB4aTkxQXSplIm4XSGLsgXA5AQ9axgNdvuuMvLiwzbPvETWIiLHTwhztyzCrHPppfJ9caydJDi8gbZGDKXXLlbZO6sUv2ZrZJ-nafzvuav9U-3aOzvn369ib54SCY1gimLYJpi2C6rqhFMO0RTHsEU0Aw7RFMawRTRDDtEEyfIn6fPaeHFLBLW-zSDrsvbpEPr6bzyZHXEIZ4Guzk2JM5z3wjdDTOuVBMhwqc6UiLHIzuTIXShDxLxoGUKhnz0MRK5FGSKKGVBLeG5ew22Smr0twhlCVGZblMJIsyHoUwJ8hykzGhVO5zru4Sv33f6ZntC5P-Rdb3Lj7lPrna_xMekJ31cmMekkurbPOoBsxPpgG5ew |
link.rule.ids | 315,782,786,27933,27934 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nephrectomy+after+complete+response+to+immune+checkpoint+inhibitors+for+metastatic+renal+cell+carcinoma+%28mRCC%29%3A+A+new+surgical+challenge%3F&rft.jtitle=Journal+of+clinical+oncology&rft.au=Pignot%2C+Geraldine&rft.au=Thiery-Vuillemin%2C+Antoine&rft.au=Walz%2C+Jochen&rft.au=Lang%2C+Herve&rft.date=2020-02-20&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=38&rft.issue=6_suppl&rft.spage=707&rft.epage=707&rft_id=info:doi/10.1200%2FJCO.2020.38.6_suppl.707&rft.externalDBID=n%2Fa&rft.externalDocID=10_1200_JCO_2020_38_6_suppl_707 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |